The Laboratory for Genomics Research (LGR), a collaboration between UC Berkeley/UCSF (IGI) and GlaxoSmithKline, has focused the Excellence in Research Award (ERA) to fund ten COVID-19 research projects at UC Berkeley and UCSF. The projects are:
- Exploring SARS-CoV-2 viruses using CRISPR-based yeast recombineering.
Raul Andino and Hiten Madhani, UCSF. Read more >
- Epigenome editing: a new prophylactic SARS-CoV-2 therapeutic.
Luke Gilbert, UCSF and Jonathan Weissman, Whitehead Institute. Read more >
- Inhibiting SARS-CoV-2 virulence protein function using functional genomics and structural biology.
Britt Glaunsinger, UC Berkeley. Read more >
- Discovering and targeting the RNA structural code underlying SARS-CoV-2 life-cycle.
Hani Goodarzi, UCSF. Read more >
- Identification of host-dependency factors for SARS-CoV-2.
Nevan Krogan, UCSF. Read more >
- Detection of active SARS-CoV-2 infections in crude and complex biofluids.
Markita Landry, UC Berkeley. Read more >
- Rapid, low-cost, high-throughput viral and metagenome sequencing of COVID-19 patient samples for outbreak surveillance.
Liana Lareau and Stacia Wyman, UC Berkeley. Read more >
- A Cas9-based shuttle enhancing cellular import and nuclear localization of plasmid DNA as an adjuvant of non-viral SARS-CoV-2 DNA vaccines entering human trials.
Alex Marson, UCSF and Ross Wilson, UC Berkeley. Read more >
- The QCRG structural consortium: targeting the host-pathogen interface.
Oren Rosenberg, UCSF. Read more >
- Determining factors that inhibit the interaction between COVID19 and its receptor on lung epithelial cells.
Robert Stroud, UCSF. Read more >
The LGR, located adjacent to UCSF’s Mission Bay campus, was established in 2019. It is a state-of-the-art functional genomics laboratory for CRISPR technologies.
Given the urgency of the COVID-19 pandemic, the LGR is giving this year’s ERA funding to projects that will rapidly address COVID-19. Research results are expected in 6–12 months. Each award is approximately $100K, accelerating the rate of COVID-19 research being done in the Bay Area.
This work is funded by the Laboratory for Genomics Research (LGR), a collaboration between UC Berkeley/UCSF (IGI) and GlaxoSmithKline.